Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE:DHR) will redeem €800,000,000 of 2.500% Senior Notes due 2025. The redemption price includes the principal amount, a make-whole premium, and accrued interest. This action will occur on December 29, 2021. Danaher is a global technology innovator in health care and environmental markets, committed to solving complex challenges. With over 69,000 associates, the company maintains a strong operational culture based on the Danaher Business System.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the Evercore ISI HealthCONx Conference on December 1, 2021, at 1:00 p.m. ET. The presentation will be webcast live on www.danaher.com. Danaher is a leader in science and technology, dedicated to solving complex challenges in health care, environmental, and applied markets, with around 69,000 associates globally. For further details, visit their website.
Danaher Corporation (NYSE: DHR) reported strong third-quarter results for 2021, achieving net earnings of $1.2 billion or $1.54 per diluted share, marking a 33% YoY increase. Revenues surged 23% YoY to $7.2 billion, with non-GAAP core revenue growth of 20.5%. The company also noted significant increases in operating cash flow and free cash flow, up 51% and 46.5% YoY, respectively. Looking ahead, Danaher expects non-GAAP core revenue growth in the low-to-mid teens for Q4 and over 20% for the full year 2021. The recent acquisition of Aldevron is set to bolster its genomic medicine capabilities.
Summary not available.
Beckman Coulter has launched the DxU Iris Workcell, an automated urinalysis system, at the AACC Annual Scientific Meeting on September 28, 2021. This innovative system reduces manual reviews to 4% and minimizes workflow disruptions in laboratories. The DxU Iris Workcell integrates advanced technology for enhanced accuracy and standardization in urinalysis, addressing increased laboratory demands, especially post-pandemic. It features a Load and Unload station for managing 190 samples and is designed for high-volume laboratories, promoting faster turnaround times and improved laboratory efficiency.
Danaher Corporation (NYSE: DHR) will host its third quarter 2021 earnings conference call on October 21, 2021, at 8:00 a.m. ET. The call will last about one hour and will be available via webcast on Danaher's website. A replay will follow shortly after and remain accessible until November 4, 2021. The earnings press release and presentation materials will be posted at 6:00 a.m. ET on the same day.
Danaher focuses on science and technology solutions, impacting healthcare and environmental sectors with over 69,000 associates.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.21 per share on common stock, payable on October 29, 2021, to record holders as of September 30, 2021. Additionally, the company announced dividends for its Series A and Series B Mandatory Convertible Preferred Stock: $11.875 and $12.50 per share, respectively, both payable on October 15, 2021, to holders of record on September 30, 2021.
SCIEX has launched the BioPhase 8800 system, a groundbreaking capillary electrophoresis solution enabling simultaneous processing of eight samples. This innovation addresses the growing complexities in biopharmaceutical development, enhancing the speed and accuracy of analyses critical for next-gen drug development. Key features include high throughput, integrated detection modules, and user-friendly software, promising to shorten analysis time from one month to just one week. As part of Danaher (NYSE: DHR), SCIEX continues to lead in solutions that enhance bioprocessing efficiency.
SCIEX, a Danaher company, has launched Biologics Explorer software for the ZenoTOF 7600 system, enhancing protein characterization analysis for biopharmaceuticals. This software enables scientists to optimize processing steps, delivering actionable insights from complex protein spectra. The strategic partnership with Genedata promotes further capabilities, allowing workflows for intact analysis, PTM determination, peptide mapping, and more. This innovation aims to expedite the development of life-saving protein therapeutics, illustrating SCIEX's commitment to advancing biopharma technology.
Danaher Corporation (NYSE: DHR) has successfully completed its acquisition of Aldevron, which will now function as a standalone entity within Danaher's Life Sciences segment. The acquisition aligns with Danaher's commitment to solving complex challenges in various sectors, including health care. With a diverse team of approximately 69,000 associates, Danaher aims to leverage this acquisition to enhance its operational capabilities and market position.